A shot in the arm for Pharmaniaga

TheStar Wed, Nov 17, 2021 10:00am - 2 years View Original


MIDF Research maintained its “buy’’ call with unchanged target price of 98 sen per share.

PETALING JAYA: Pharmaniaga Bhd’s initiative of supplying vaccines out of Malaysia will see its business prospering beyond the local sector.

Its long-term prospects also remains positive and with the group’s other strategies in providing access to its pharmaceuticals as well as increasing capacities and capabilities.

However, the collaboration with Myanmar to distribute Sinovac vaccines has been factored in for the current quarter, and will not have an extreme effect on the group’s earnings for the year.

...

Full Article on TheStar

The content is a snapshot from Publisher. Refer to the original content for accurate info. Contact us for any changes.






Related Stocks

PHARMA 0.335

Comments

Login to comment.